Allakos Inc. (ALLK)

Market Cap	74.43M
Revenue (ttm)	n/a
Net Income (ttm)	-214.44M
Shares Out	88.54M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	756,169
Open	0.890
Previous Close	0.880
Day's Range	0.833 - 0.932
52-Week Range	0.833 - 5.640
Beta	0.91
Analysts	Hold
Price Target	1.83 (+117.7%)
Earnings Date	Aug 7, 2024

About ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 2018
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLK

Analyst Forecast

According to 5 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1.83, which is an increase of 117.70% from the latest price.

Price Target

$1.83

(117.70% upside)

Analyst Consensus: Hold